Takeda leads Asia's acquisitive charge in 2012/13
This article was originally published in Scrip
Executive Summary
Out of a total of 19 corporate acquisition or financing deals completed in Asia over the April 2012-March 2013 period, it comes as no surprise to see Asia's largest homegrown pharma firm, Japan's Takeda, take home the prize for sheer number of transactions.
You may also be interested in...
ASCO 2020: Positive Early Data For Keytruda/Lenvima In Liver, Kidney Cancer
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
Need a specific report? 1000+ reports available
Buy Reports